Literature DB >> 33390169

Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy.

Ajaz A Bhat1, Sabah Nisar1, Selma Maacha2, Tatiana Correa Carneiro-Lobo3, Sabah Akhtar4, Kodappully Sivaraman Siveen4, Nissar A Wani5, Arshi Rizwan6, Puneet Bagga7, Mayank Singh8, Ravinder Reddy9, Shahab Uddin4, Jean-Charles Grivel2, Gyan Chand10, Michael P Frenneaux11, Mushtaq A Siddiqi12, Davide Bedognetti3,13,14, Wael El-Rifai15, Muzafar A Macha16, Mohammad Haris17,18.   

Abstract

Esophageal cancer (EC) is a disease often marked by aggressive growth and poor prognosis. Lack of targeted therapies, resistance to chemoradiation therapy, and distant metastases among patients with advanced disease account for the high mortality rate. The tumor microenvironment (TME) contains several cell types, including fibroblasts, immune cells, adipocytes, stromal proteins, and growth factors, which play a significant role in supporting the growth and aggressive behavior of cancer cells. The complex and dynamic interactions of the secreted cytokines, chemokines, growth factors, and their receptors mediate chronic inflammation and immunosuppressive TME favoring tumor progression, metastasis, and decreased response to therapy. The molecular changes in the TME are used as biological markers for diagnosis, prognosis, and response to treatment in patients. This review highlighted the novel insights into the understanding and functional impact of deregulated cytokines and chemokines in imparting aggressive EC, stressing the nature and therapeutic consequences of the cytokine-chemokine network. We also discuss cytokine-chemokine oncogenic potential by contributing to the Epithelial-Mesenchymal Transition (EMT), angiogenesis, immunosuppression, metastatic niche, and therapeutic resistance development. In addition, it discusses the wide range of changes and intracellular signaling pathways that occur in the TME. Overall, this is a relatively unexplored field that could provide crucial insights into tumor immunology and encourage the effective application of modulatory cytokine-chemokine therapy to EC.

Entities:  

Keywords:  Chemokines; Cytokines; Drug targets; Epithelial-Mesenchymal transition; Esophageal cancer; Immune evasion; Inflammation; Tumor microenvironment

Year:  2021        PMID: 33390169     DOI: 10.1186/s12943-020-01294-3

Source DB:  PubMed          Journal:  Mol Cancer        ISSN: 1476-4598            Impact factor:   27.401


  185 in total

Review 1.  Squamous cell cancer of the oesophagus.

Authors:  H Messmann
Journal:  Best Pract Res Clin Gastroenterol       Date:  2001-04       Impact factor: 3.043

Review 2.  Epidemiology of esophageal adenocarcinoma.

Authors:  Manuel Pera; Carlos Manterola; Oscar Vidal; Luis Grande
Journal:  J Surg Oncol       Date:  2005-12-01       Impact factor: 3.454

3.  Esophageal carcinoma.

Authors:  Anil K Rustgi; Hashem B El-Serag
Journal:  N Engl J Med       Date:  2014-12-25       Impact factor: 91.245

Review 4.  Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.

Authors:  Branislav Bystricky; Alicia F C Okines; David Cunningham
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

5.  Novel targets in gastric and esophageal cancer.

Authors:  Claudia María Valverde; Teresa Macarulla; Esther Casado; Francisco Javier Ramos; Erika Martinelli; Josep Tabernero
Journal:  Crit Rev Oncol Hematol       Date:  2006-07-10       Impact factor: 6.312

Review 6.  Angiogenesis in superficial esophageal squamous cell carcinoma: magnifying endoscopic observation and molecular analysis.

Authors:  Youichi Kumagai; Masakazu Toi; Kenro Kawada; Tatsuyuki Kawano
Journal:  Dig Endosc       Date:  2010-08-12       Impact factor: 7.559

7.  Bile acids as endogenous etiologic agents in gastrointestinal cancer.

Authors:  Harris Bernstein; Carol Bernstein; Claire M Payne; Katerina Dvorak
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

Review 8.  Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis.

Authors:  Brian J Reid; Xiaohong Li; Patricia C Galipeau; Thomas L Vaughan
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

9.  The bile acid deoxycholic acid has a non-linear dose response for DNA damage and possibly NF-kappaB activation in oesophageal cells, with a mechanism of action involving ROS.

Authors:  G J S Jenkins; J Cronin; A Alhamdani; N Rawat; F D'Souza; T Thomas; Z Eltahir; A P Griffiths; J N Baxter
Journal:  Mutagenesis       Date:  2008-05-30       Impact factor: 3.000

Review 10.  Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities.

Authors:  Christophe Mariette; Guillaume Piessen; Jean-Pierre Triboulet
Journal:  Lancet Oncol       Date:  2007-06       Impact factor: 41.316

View more
  25 in total

1.  Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.

Authors:  Tao Fan; Yu Liu; Hengchang Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Fengwei Tan; Qi Xue; Shungeng Gao; Chunxiang Li; Jie He
Journal:  Cancer Immunol Immunother       Date:  2021-05-11       Impact factor: 6.968

Review 2.  Does CCL19 act as a double-edged sword in cancer development?

Authors:  Arezoo Gowhari Shabgah; Zaid Mahdi Jaber Al-Obaidi; Heshu Sulaiman Rahman; Walid Kamal Abdelbasset; Wanich Suksatan; Dmitry O Bokov; Lakshmi Thangavelu; Abduladheem Turki Jalil; Farhad Jadidi-Niaragh; Hamed Mohammadi; Kazem Mashayekhi; Jamshid Gholizadeh Navashenaq
Journal:  Clin Exp Immunol       Date:  2022-04-04       Impact factor: 4.330

3.  The expression of FLNA and CLU in PBMCs as a novel screening marker for hepatocellular carcinoma.

Authors:  Rathasapa Patarat; Shoji Riku; Pattapon Kunadirek; Natthaya Chuaypen; Pisit Tangkijvanich; Apiwat Mutirangura; Charoenchai Puttipanyalears
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

4.  Chemokines in Prediabetes and Type 2 Diabetes: A Meta-Analysis.

Authors:  Xiongfeng Pan; Atipatsa C Kaminga; Shi Wu Wen; Aizhong Liu
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

5.  Weighted Gene Correlation Network Analysis Identifies Specific Functional Modules and Genes in Esophageal Cancer.

Authors:  Wei Xu; Jian Xu; Zhiqiang Wang; Yuequan Jiang
Journal:  J Oncol       Date:  2021-12-27       Impact factor: 4.375

6.  A Population-Based Study: How to Identify High-Risk T1-2 Esophageal Cancer Patients?

Authors:  Yiming Qi; Shuangshuang Wu; Linghui Tao; Guoshu Xu; Jiabin Chen; Zhengquan Feng; Chao Lu; Yanli Wan; Jing Li
Journal:  Front Oncol       Date:  2021-12-13       Impact factor: 6.244

Review 7.  Roles of G Protein-Coupled Receptors (GPCRs) in Gastrointestinal Cancers: Focus on Sphingosine 1-Shosphate Receptors, Angiotensin II Receptors, and Estrogen-Related GPCRs.

Authors:  Zhen Zeng; Chunxiang Ma; Kexin Chen; Mingshan Jiang; Reshma Vasu; Rui Liu; Yinglan Zhao; Hu Zhang
Journal:  Cells       Date:  2021-11-03       Impact factor: 6.600

8.  Decreased IL-6 and NK Cells in Early-Stage Lung Adenocarcinoma Presenting as Ground-Glass Opacity.

Authors:  Pengfei Zhang; Boxue He; Qidong Cai; Guangxu Tu; Xiong Peng; Zhenyu Zhao; Weilin Peng; Fenglei Yu; Min Wang; Yongguang Tao; Xiang Wang
Journal:  Front Oncol       Date:  2021-09-08       Impact factor: 6.244

9.  lncRNA MIAT/HMGB1 Axis Is Involved in Cisplatin Resistance via Regulating IL6-Mediated Activation of the JAK2/STAT3 Pathway in Nasopharyngeal Carcinoma.

Authors:  Xuewei Zhu; Li Liu; Yang Wang; Jianan Cong; Zhang Lin; Yongsen Wang; Qi Liu; Leiming Wang; Ben Yang; Tao Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

Review 10.  Cancer Stem Cells and Their Vesicles, Together with Other Stem and Non-Stem Cells, Govern Critical Cancer Processes: Perspectives for Medical Development.

Authors:  Jacopo Meldolesi
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.